Miller et al. demonstrated that the inhibition of CD73 using a specific antibody stimulates CD73+ B cells, promoting antigen-specific immune responses with protective immune characteristics, and inducing B cell redistribution in lymphoid tissues in cancer patients [45]. This evidence concerns the gene NT5E and cancer.